Last reviewed · How we verify

NCT05568602

Appropriate Limit Value for 1 mg DST in Patients With Chronic Renal Failure

Completed Last updated 5 October 2022
What this trial tests

trial testing Dexamethasone suppression test in Cushing Syndrome in 1,034 participants. Completed in 1 August 2021.

Timeline
1 June 2020
Primary endpoint
1 June 2021
1 August 2021

Quick facts

Lead sponsorMarmara University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,034
Start date1 June 2020
Primary completion1 June 2021
Estimated completion1 August 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Marmara University

Who can join

Adults 18 to 80, any sex, with Cushing Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, we aimed to determine a specific cut-off value for 1mg DST to prevent false positivity usually seen in CRF patients according to the standard cut-off value of 1.8 mcg/dl.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Hair cortisol and changes in cortisol dynamics in chronic kidney disease.
    Boswell L, Vega-Beyhart A, Blasco M, Quintana LF, et al · · 2024 · cited 6× · PMID 38638132 · DOI 10.3389/fendo.2024.1282564

Verify or expand the search:

Other trials of Dexamethasone suppression test

Trials testing the same drug.

Other recruiting trials for Cushing Syndrome

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05568602.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing